Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
pipeline
Biotech
BioVie cuts 'most de-risked program,' will seek partner
BioVie is seeking partners for its “most de-risked program,” a phase 3-ready investigational infusion for patients with refractory ascites.
Gabrielle Masson
Mar 11, 2024 11:12am
Pfizer revamps oncology R&D strategy
Feb 29, 2024 6:03pm
Goldilocks and the 'not great, but good enough' development deal
Feb 27, 2024 4:00am
Galapagos halts lupus CAR-T work, confirms 100 layoffs this year
Feb 23, 2024 8:28am
Bavarian Nordic halts cancer vaccine program
Feb 21, 2024 7:25am
AstraZeneca axes IL-33 kidney disease program after seeing data
Feb 8, 2024 5:30am